YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558) has released an update.
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. has announced a significant upward revision of its annual caps for leasing and other services due to a rapid business growth and increased marketing activities. The adjustments are intended to support market opportunities and enhance the branding of their core products, with a particular increase expected in demand for inspection and testing services. These revised caps for the years ending 31 December 2024 and 2025 will maintain the existing terms of their Leasing and Other Services Framework Agreement.
For further insights into HK:1558 stock, check out TipRanks’ Stock Analysis page.
